EDAP and Telix Partner to Advance Precision Prostate Cancer Treatment Through HIFU-PSMA PET Integration
核心洞察
EDAP TMS and Telix Pharmaceuticals have entered a letter of intent to explore combining Focal One Robotic HIFU (搜索) with PSMA PET imaging (搜索) for enhanced prostate cancer (搜索) management.
The collaboration aims to integrate PSMA (搜索) PET diagnostic scans into the HIFU treatment workflow to optimize planning, delivery, and monitoring in both primary and salvage treatment settings.
Early clinical experience and the recent HIFI-2 study demonstrate positive outcomes using Focal One for radiation therapy recurrence, suggesting potential for improved patient outcomes through this precision medicine approach.
EDAP TMS S.A. (搜索) and Telix Pharmaceuticals Limited (搜索) have announced a strategic collaboration to advance precision medicine in prostate cancer (搜索) treatment through the integration of robotic high-intensity focused ultrasound (HIFU) technology with PSMA PET imaging (搜索). The companies entered into a letter of intent on May 14, 2026, to explore joint clinical research activities and physician education programs.
Combining Advanced Imaging with Robotic Therapy
The collaboration focuses on integrating Telix's PSMA (搜索) PET diagnostic imaging scans within EDAP's Focal One HIFU treatment workflow. This combination aims to optimize treatment planning, deliver precise image-guided focal therapy, and monitor patient responses during treatment and follow-up periods. The investigational approach will be studied in both primary treatment settings and salvage treatment scenarios following radiation therapy.
"We are uniquely designed to enable the integration of PSMA PET imaging (搜索) with Focal One's real-time ultrasound and fully robotic energy delivery to optimize treatment efficacy while minimizing side effects," said Ryan Rhodes, EDAP Chief Executive Officer. The company positions itself as the market leader in robotic focal therapy with a growing global installed base.
Clinical Foundation and Future Potential
The collaboration builds on early clinical experience integrating PSMA (搜索) PET with Focal One HIFU and the recently published prospective HIFI-2 study, which demonstrated positive patient outcomes using Focal One to treat patients with recurrence after radiation therapy. This clinical foundation supports the potential for further improving patient outcomes through the combined approach.
Kevin Richardson, Telix Precision Medicine Chief Executive Officer, emphasized the precision medicine aspect: "Precision medicine requires precision treatment strategies. As disruptive technologies continue to transform prostate cancer (搜索) care, we believe PSMA PET imaging (搜索) has the potential to play an important role in helping clinicians better inform treatment decisions across a range of minimally invasive and image-guided treatment approaches."
Educational and Research Initiatives
Beyond clinical research, the partnership may encompass clinician educational programs including webinars, symposia, and training initiatives. The companies also plan to explore clinical studies involving mutual customers managing patients with Telix PSMA PET imaging (搜索) products and Focal One Robotic HIFU (搜索).
Collaboration Structure and Financial Impact
The current agreement represents a letter of intent with no financial commitments from either party. The companies may enter into more definitive agreements in the future, though there is no assurance that specific initiatives or programs will result from this initial collaboration. EDAP expects the collaboration will not have a material impact on its financial results.
EDAP TMS develops and distributes minimally invasive medical devices using ultrasound technology, combining imaging, robotics, and precise non-invasive energy delivery. The Focal One platform has been introduced in Europe and the United States as a leading prostate focal therapy system controlled by urologists, with potential expansion to multiple indications beyond prostate cancer (搜索).
Telix Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address unmet medical needs in oncology and rare diseases. The company operates internationally with headquarters in Melbourne, Australia, and maintains operations across the United States, United Kingdom, Brazil, Canada, Europe, and Japan.